1. Acharya, V.L., Lowe, C.U., Thapa, R., Gurubacharya, V.L., Shrestha, M.B., Cadoz, M., Schulz, D., Armand, J., Bryla, D., Trollfors, B., Cramton, T., Schneerson, R. and Robbins, J.B., 1987, Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report, N. Engt J. Med., 317: 1101.
2. Anderson, P.W., Pichichero, M.E., Insel, R.A, Betts, R., Eby, R. and Smith, D.H., 1983, Vaccines consisting of periodate cleaved oligosaccharides from the capsule of Haemophilus influenzae type b coupled to a protein carrier: structural and temporal requirements for priming in the human infant, J.Jmmunol., 137:1181.
3. Beuvery, E.C., van Rossum, F. and Nagel, J., 1982, Comparison of the induction of immunoglobulin M and G antibodies in mice with purified pneumococcal type 3 and meningococcal group C polsaccharides and their protein conjugates, Infect. Immun., 37:15.
4. Cryz, S.J., Sadoff, J.C., Furer, E. and Germanier, R., 1986, Pseudomnas aeruginosa polysaccharidetetanus toxoid conjugate vaccine: safety and immunogenicity in humans, J. Infect Dis., 154:682.
5. Dick, W.E. and Beurret, M., 1989, Glycoconjugates of bacterial carbohydrate antigens. A survey and consideration of design and preparation factors, in: “Conjugate Vaccines”, J.M. Cruse and R.E. Lewis, Jr., ed., Karger, Basel.